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Abstract
$O]KHLPHU·V GLVHDVH LV D FRPPRQ QHXURGHJHQHUDWLYH GLVHDVH WKDW LV WKH WK OHDGLQJ FDXVH RI GHDWK LQ WKH 8QLWHG 6WDWHV$Q
HVWLPDWHGPLOOLRQ$PHULFDQVDUHDIÁLFWHGQDWLRQZLGHDQGWKHFRVWWRWKHHFRQRP\LVYDOXHGDWELOOLRQGROODUV$GGLWLRQDOO\
XQOLNHRWKHUPDMRUFDXVHVRIGHDWKLQWKH8QLWHG6WDWHVWKHUHLVQRWUHDWPHQWIRU$O]KHLPHU·V'LVHDVH$O]KHLPHU·VLVDSURJUHVVLYHGLVHDVHDQGLWLVVWURQJO\WLHGWRDJLQJ ,QPRVWFDVHVV\PSWRPVPDNHWKHLUÀUVWDSSHDUDQFHLQWKHODWH·VDQGJUDGXDOO\
worsen, eventually leading to a loss of cognitive function and death. The two outstanding changes in the brain associated with
$O]KHLPHU·VGLVHDVHDUHQHXURÀEULOODU\WDQJOHVDQGEHWDDP\ORLGSODTXH7KHSUHVHQFHRIWKHVHLVXVHGWRGLDJQRVH$O]KHLPHU·V
GLVHDVHDIWHUGHDWK &HUWDLQKRUPRQDOFKDQJHVWKDWDUHDVVRFLDWHGZLWKDJH VXFKDVDULVHLQOXWHLQL]LQJKRUPRQHOHYHOV DUH
VWURQJFRQWHQGHUVIRUWKHDJHUHODWHGFDXVHVRI$O]KHLPHU·VGLVHDVH(OHYDWHGJRQDGRWURSLQOHYHOVKDYHEHHQVKRZQLQVWXGLHVWR
correlate with amyloid beta accumulation in human and animal brains. The precise mechanism of action and the causation are
QRW\HWIXOO\XQGHUVWRRG1HYHUWKHOHVVVRPHVWXGLHVKDYHVKRZQWKDWORZHULQJOHYHOVRI*RQDGRWURSLQUHOHDVLQJKRUPRQH ZKLFK
UHOHDVHVOXWHLQL]LQJKRUPRQH WKURXJKWKHWUHDWPHQWZLWK/HXSUROLGHDFHWDWHDJRQDGRWURSLQUHOHDVLQJKRUPRQHDJRQLVWKDYHOHG
WRORZHUHGULVNRIPRUWDOLW\E\$O]KHLPHU·VGLVHDVHLQERWKPLFHDQGKXPDQV7KLVSDSHUZLOOGLVFXVVWKHDVVRFLDWLRQEHWZHHQHOHYDWHGOXWHLQL]LQJKRUPRQHOHYHOVDQG$O]KHLPHU·VGLVHDVHDVZHOODVWKHSRVVLELOLW\RID*RQDGRWURSLQUHOHDVLQJKRUPRQHEORFNLQJ
EDVHGWUHDWPHQWIRU$O]KHLPHU·V
Introduction
$O]KHLPHU·VGLVHDVHLVQDPHGDIWHU'U$ORLV$O]KHLPHUZKRÀUVW
discovered the disease in 1906. Dr. Alzheimer had a patient with
severe memory loss, aphasia, and unnatural behavior who died
of complications related to her disease. Upon her death, he
performed an autopsy and noticed two unusual features in the
EUDLQWDQJOHVRIÀEHUVDQGSURWXEHUDQFHV:HQRZNQRZWKHVH
DVQHXURÀEULOODU\WDQJOHVDQGEHWDDP\ORLGSODTXHV,WLVGLIÀFXOW
to accurately measure tangles and plaques during the lifetime
of a patient with the disease; therefore, Alzheimer’s disease is
diagnosed based on symptoms. The symptoms that are used to
diagnose Alzheimer’s disease today are much like those of Dr.
Alzheimer’s original patient. The common symptoms are memory related issues, trouble with organizational skills, getting lost,
confusion, and personality changes. Eventually the deterioration
escalates and the patient may hallucinate, become unable to
recognize others, and then become unable to talk or eat. Lastly,
the parts of the brain that directly control living processes are
affected and death occurs. (National Institute on Aging, 2012)
The progression of Alzheimer’s disease does not happen
quickly, in fact Alzheimer’s is a very slowly progressing disease,
DQGWKHUHLVXVXDOO\\HDUVEHWZHHQWKHÀUVWDSSHDUDQFHRI
symptoms and death. This being the case, it is theorized that
even before symptoms occur, perhaps years prior, there is a
IRUPRI´SUH$O]KHLPHU·Vµ7KLVFDQEHGHÀQHGDVDV\PSWRPDWLF
FKDQJHVLQWKHEUDLQZKLFKDUHWKHWUXHÀUVWVWHSVRI$O]KHLPHU·V
disease. The ability to detect these changes would greatly assist
LQWKHVWUXJJOHWRÀQGDFXUHDQGLVFXUUHQWO\EHLQJUHVHDUFKHG
(National Institute on Aging, 2012)
Unfortunately, it is not possible with our current level of
technology to reliably detect the changes in the brain that are
present in Alzheimer’s, even advanced Alzheimer’s. Although we
have come a long way with neuroimaging methods, they are unable to determine Alzheimer’s disease directly. Instead, after the
onset of symptoms, brain imaging techniques such as MRIs and
PET scans are used to rule out other probable causes of brain

dysfunction; such as stroke or other forms of dementia. If these
are not indicated, a diagnosis of probable Alzheimer’s is given
XQWLOGHDWKDQGDXWRSV\8SRQDXWRSV\LIWKHUHDUHQHXURÀEULOODU\WDQJOHVDQGDP\ORLGSODTXHVWKHGLDJQRVLVLVWKHQFRQÀUPHG
(National Institute on Aging, 2015).
1HXURÀEULOODU\WDQJOHVDQGEHWDDP\ORLGSODTXHDUHWKHWZR
PDLQ SK\VLFDO SKHQRPHQD WKDW GHÀQH$O]KHLPHU·V GLVHDVH EXW
WKH PHFKDQLVP WKDW WKH\ XVH WR LQÁXHQFH$O]KLHPHU·V GLVHDVH
and cause the deterioration of the brain is not yet understood.
1HXURÀEULOODU\ WDQJOHV DUH DOVR FDOOHG WDX WDQJOHV DV WKH\ DUH
composed and caused by defective tau proteins. Tau proteins
are microtubule-associated proteins that are common in the
central nervous system. In a healthy person, these tau proteins
hold microtubules in place and keep them steady. However in
Alzheimer’s disease the tau proteins become hyperphosphorylated and they cease to support the microtubules. The microtubules unwind and collapse and the hyperphosphorylated tau
EXLOGVXS7RJHWKHUWKH\IRUPÀODPHQWRXVFOXPSVZKLFKDUHWKH
QHXURÀEULOODU\WDQJOHVRI$O]KHLPHU·VGLVHDVH,WLVQRWFHUWDLQLI
the tangles participate in the cause of Alzheimer’s disease or are
just an effect of it (C. Bancher, 1989). However, the density of
the tau tangles correlates with the extent of dementia and they
are located in the affected brain areas. A possible mechanism
E\ZKLFKWKHEUDLQGHJHQHUDWHGE\QHXURÀEULOODU\WDQJOHVLVDV
follows. When disrupted microtubules are abundant, the neuron is weakened and it becomes unable to transmit impulses
at a normal rate. The body’s immune system detects compromised neurons and triggers apoptosis of the cells (Wang, Xia,
Grundke-Iqbal, & Iqbal, 2013).
7KHPRUHVLJQLÀFDQW$O]KHLPHU·VGLVHDVHPDUNHULVEHWDDP\loid plaque. In the healthy brain, tangles and plaques are present
in small quantities and pose no problem. It is when the beta
amyloid amounts build up that issues arise. It is understood that
this build up is the result of a difference between the amount
of beta amyloid plaque that is formed and the amount that is
removed. Beta amyloid plaque is formed by the breakdown of
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)LJXUH1XHURÀEULOODU\WDQJOHVLQWKH+LSSRFDPSXVRIDQHOGHUO\PDQZLWK$O]KHLPHU·VUHODWHGSDWKRORJ\
$ERYH7KHWDQJOHLVHQODUJHGDQGLVYLVLEOHDERYHWKHWKHGDUNVWDLQ  3DWKR 
amyloid precursor protein (APP), which is present in the synapses of neurons.APP is present all over the brain and is thought
to perform a function relating to neuron growth (Thinamaran
& Koo, 2008). APP is broken down by several enzymes known
as alpha, beta, and gamma secretase. When amyloid precursor
protein is broken down by a combination of alpha and gamma
secretase it forms a protein called њAPP which may have effects
that protect the brain (Krishnaswamy, Verdile, Groth, Kanyenda,
& Martins, 2009). However, when beta secretase takes the place
of alpha secretase, it forms beta amyloid, which is sticky and insoluble allowing it to form plaques.The process of how beta amyloid plaque is removed from the brain is not fully understood
but it could be performed in a variety of ways including protein

transport through the blood or destruction by enzymes, such
as insulin. Beta amyloid plaque is neurotoxic and it can inhibit
synapse formation, disrupt mitochondrial action, contribute to
LQÁDPPDWLRQLQWKHEUDLQDQGSURPRWHWKHK\SHUSRODUL]DWLRQRI
WDX SURWHLQV ZKLFK LQ WXUQ FDXVHV QHXURÀEULOODU\ WDQJOHV %HWD
DP\ORLG SODTXHV PD\ EH PRUH LPSRUWDQW WKDQ QHXURÀEULOODU\
tangles and tau proteins in the onset of age related Alzheimer’s.
Other diseases have tangles but Alzheimer’s disease is associated with plaque formation. (Lee, Goedert, & Trojanowski, 2001)
Additionally, it is supposed that beta amyloid plaque forms earlier in the progression of Alzheimer’s disease and contributes to
WKHQHXURÀEULOODU\WDQJOHV 9LOOHPDJQHHWDO 7KLVWKHRU\
WKDW EHWD DP\ORLG SODTXH LV WKH PRVW VLJQLÀFDQW IDFWRU LQ WKH
)LJXUH&HUHEUDODXWRSV\VSHFLPHQ
of a patient diagnosed with Alzheimer
'LVHDVH,QWKH+(VWDLQQXPHURXV
plaque formations within the neuropil
EDFNJURXQGDUHYLVLEOH 1HXURÀEULOODU\
tangles in the Hippocampus of
a person with Alzheimer-related
SDWKRORJ\+(-3*  3DWKR

72

Luteinizing Hormone and Alzheimer’s Disease: Impact and Possibilities of Treatment

pathogenesis of Alzheimer’s is called the “amyloid hypothesis”
(Burnham & Thornton, 2015).
There are two forms of Alzheimer’s and they have inherently
different causes. Early onset Alzheimer’s is when Alzheimer’s
disease occurs to people under 65. Most people with this form
of the disease have a mutation in one of three genes, APP, PSEN
1, and PSEN 2. These mutations run in families and create a
disposition to suffer from early onset Alzheimer’s. (Bird, 2015)
This is a genetic disease but it is far less common than late
onset Alzheimer’s disease and it accounts for about 5 percent of
total Alzheimer’s cases. In late onset Alzheimer’s disease, there
is also a genetic component connected with the APOE gene
but the main risk factor is age. The older someone is, the more
they are at risk of late onset Alzheimer’s disease. The reasons
why age should increase risk for Alzheimer’s disease are not yet
understood. Research is being done into the natural changes
that occur in the body with age as possible contributors to
Alzheimer’s disease. The age-related changes to the hypothalamic/pituitary/gonadal feedback loop that regulates sex hormone levels in the blood is a strong candidate for this research.
The sex hormones are produced in the context of a feedback loop with Gonadotropin-releasing hormone in the hypothalamus and the gonadotropins, luteinizing hormone and
follicle stimulating hormone which are released by the pituitary
gland. In a healthy individual, Gonadotropin-releasing hormone
is released from the hypothalamus in surges in response to internal and environmental factors. It travels to the anterior pituitary gland where it stimulates gonadotropic cells to produce
luteinizing hormone and follicle stimulating hormone These
hormones travel to the gonads, the testicles and the ovaries,
and they stimulate them to release testosterone and estrogen

respectively.To prevent too much of these hormones from being
PDGHWHVWRVWHURQHDQGHVWURJHQLQVXIÀFLHQWTXDQWLWLHVSURYLGH
negative feedback that discourages the further production of
GnRH by the hypothalamus. However, with advancing age the
process changes. Testosterone levels fall gradually in men, and in
women estrogen drops rapidly after menopause. Without the
negative feedback of the endpoint, gonadotropin levels tend to
rise, although this is not true in all cases. (Jones, 2012)
For many years it was thought that the lowered levels of
testosterone and estrogen that come with age were involved in
the cause of Alzheimer’s. It was assumed that these hormones
had neuroprotective properties and their absence allowed
Alzheimer’s disease to creep in. However, it was found that
giving testosterone or estrogen directly did not lower risk for
Alzheimer’s disease and in fact raised it. (Manly, et al., 2000)
Since supplementing with testosterone/estrogen was not useful
in preventing or understanding Alzheimer’s disease, the next
logical step was to look at the heightened levels of gonadotropins that relate to the lower sex hormone levels. However,
even in this case distinctions must be made.
Luteinizing hormone and follicle stimulating hormone are
both released by the anterior pituitary gland in response to
Gonadotropin-releasing hormone. Structurally, LH and FSH
are similar. They both are heterodimeric glycoproteins and are
composed of an alpha and beta subunit. The alpha subunit of luteinizing hormone and follicle stimulating hormone are identical,
however, the beta subunit is different and this is how they connect to different receptors and have a different scope of action.
In men, luteinizing hormone is released throughout the day and
stimulates Leydig cells to produce testosterone. Follicle stimulating hormone stimulates Sertoli cells which help sustain the

)LJXUH$IHHGEDFNORRSUHJXODWHVWKH+\SRWKDODPLF²3LWXLWDU\²*RQDGDOD[LV %RXQGOHVVFRP 
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maturing sperm cells. In women, follicle stimulating hormone
stimulates growth of the follicle in the ovary which increases
production of estradiol and estrogen. When the follicle is mature, there is a critical level of estrogen that is reached and that
stimulates a surge in luteinizing hormones, which in turn causes
the release of the egg from the follicle. LH and FSH are different
in both structure and function and how they interact with am\ORLGSODTXHDVZHOO0DQ\VWXGLHVKDYHVKRZQOLQNVVSHFLÀFDOO\
between luteinizing hormone and the levels of beta amyloid
plaque in the brain and this will be presented and evaluated.
If increased levels of luteinizing hormone contribute to
Alzheimer’s disease, it would be useful to have an explanation
for how it does so. The presence of luteinizing hormone in the
brain is not expected as it is not lipid soluble and in theory cannot cross the blood brain barrier. However luteinizing hormone
is found in the brain and it has been found that LH can pass
through this barrier in small amounts (Lukacs, Hiatt, Lei, & Rao,
1995). It is also a possible that luteinizing hormone is synthesized in the brain itself. LH receptors are found not only in the
gonads but also in the brain which would imply that it may be
active there as well. It may be that signals which are mediated by
luteinizing hormone receptors affect the processing of APP and
LQÁXHQFHLWVRLWLVPRUHOLNHO\WREHFOHDYHGE\EHWDVHFUHWDVH
than alpha secretase. This would result in a higher level of beta
amyloid plaque formed relative to њAPP and could trigger a cascade of beta amyloid plaque buildup and ultimately Alzheimer’s
disease.

Possibility of Treatment
Since elevated levels of luteinizing hormone could be a factor in the pathogenesis of Alzheimer’s disease, they are also a
target for prevention or reversal of the disease. By lowering
levels of luteinizing hormone in the blood, the contribution luteinizing hormone is making to the disease could be negated.
A potential medicine that could be effective in this therapy is
leuprolide acetate. Leuprolide, also called leuprorelin, is a synthetic hormone that is currently prescribed under the name
Lupron to treat prostate cancer, sex hormone imbalance,
and even less serious issues such as early onset of puberty
(World Health Organization, 2015). Leuprolide acts as an agonist to the Gonadotropin-releasing hormones. It binds to the
Gonadotropin-releasing hormone receptors in the pituitary
gland and interrupts their stimulation.This results in a downregulation of luteinizing hormone and follicle stimulating hormone.
Leuprolide is delivered by injection and it can be self-administered after training. It has mild short-term side effects including
dizziness, itching, and headaches. As a long-term treatment, it
can weaken bone density (Norsigian, 2005). However, with the
research we currently have, the long-term side effects do not
VHHP WR EH YHU\ VLJQLÀFDQW VSHFLÀFDOO\ ZKHQ ZHLJKHG DJDLQVW
the pathology of Alzheimer’s. The effectiveness of Leuprolide as
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a treatment to lower luteinizing hormone levels, improve cognition, and prevent or even reverse the accumulation of amyloid
plaque will be discussed in this paper.

Methods
All the information that was used in this article was gathered
from online using the Touro Library search and Google Scholar.
The search terms that were used were leuprolide acetate, leuprorelin, Alzheimer’s disease, beta amyloid plaque, luteinizing
hormone, gonadotropins, hormone, gonadotropin releasing
hormone. The articles were drawn from accepted and peer reYLHZHGVFLHQWLÀFMRXUQDOVDQGDUHDOODYDLODEOHRQOLQH:HEVLWHV
that were used were selected from dependable sources, governPHQWZHEVLWHVRUVFLHQWLÀFLQVWLWXWLRQV

Discussion:
Alzheimer’s Disease and Heightened Luteinizing
Hormone Levels in Humans
In one study, plasma samples were taken from 284 patients seen
at a tertiary care center and measured for concentrations of luteinizing hormone and follicle stimulating hormone.The patients
were divided into three groups, 134 with probable Alzheimer’s
disease, 45 with frontal temporal dementia (FTD), and 105 cognitively normal controls. The researchers logged each patient’s
score on the Mini-Mental State Examination (MMSE) to measure severity of dementia. They recorded length of sickness, the
sex and age of the subjects, and, in the case of women, if they
were taking an estrogen supplement. It was found that there
was no relationship between follicle stimulating hormone levels in men between the controls and the Alzheimer’s disease
group and although there was one with luteinizing hormone,
LW ZDV QRW VLJQLÀFDQW ZKHQ FRQWUROOHG IRU DJH7KH LPSRUWDQW
ÀQGLQJZDVWKDWLQWKHZRPHQZKRZHUHQRWWDNLQJHVWURJHQD
VLJQLÀFDQWGLIIHUHQFHLQOXWHLQL]LQJKRUPRQHOHYHOZDVREVHUYHG
compared to the controls after a univariate analysis (Figure 4)
In women who were not taking any form of estrogen, this
study found elevated levels of luteinizing hormone and follicle
stimulating hormone compared to controls. The luteinizing hormone levels were higher in the Alzheimer’s group compared
to the frontotemporal dementia group which indicates that
they were not just an effect of dementia or brain deterioraWLRQ7KHUHZDVQRVLJQLÀFDQWGLIIHUHQFHIRXQGIRUZRPHQZKR
were taking estrogen but that is not unexpected, considering
that estrogen is part of a negative feedback loop that limits luteinizing hormone production. Within the men, there was no
difference found between the FTD group and the Alzheimer’s
disease group. It is possible that this is due to the small sample
size. An important part of this study found that in estrogen free
women, there was a connection between elevated levels of gonadotropins and Alzheimer’s disease.
In a previous study by the same authors, a difference was
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WHVWVSHFLÀFDOO\IRUJRQDGRWURSLQOHYHOV1HYHUWKHOHVVWKHEORRG
that was taken was tested for it amongst other things. Some researcher reviewed the data with an eye on luteinizing hormone
and it was found that increased levels of luteinizing hormone in
the blood were correlated with beta amyloid presence in the
brain as measured by imaging techniques. This was only found in
the subjective group, which suggests that the most important link
between luteinizing hormone and beta amyloid plaque is in the
preliminary stages of Alzheimer’s disease (Ellis, et al., 2009).

Animal Trials

)LJXUH)ROOLFOHVWLPXODWLQJKRUPRQH )6+ YVOXWHLQL]LQJKRUPRQH
/+ OHYHOVLQZRPHQQRWWDNLQJHVWURJHQ1RWHWKDWVRPHSDWLHQWV
ZLWK$O]KHLPHUGLVHDVH $'  WULDQJOHV KDYHERWKKLJKHU/+DQG
)6+OHYHOVFRPSDUHGZLWKFRJQLWLYHO\QRUPDO 1/ FRQWUROVDQG
SDWLHQWVZLWKIURQWRWHPSRUDOGHPHQWLD )7'  6KRUW%RZHQ
2·%ULHQ *UDII5DGIRUG 
found for men as well. The study tested 40 males who were
diagnosed with Alzheimer’s disease in a long-term care center
and compared them to 29 controls. The study found that the
$O]KHLPHU·V GLVHDVH SDWLHQWV ZHUH VLJQLÀFDQWO\ KLJKHU LQ ERWK
luteinizing hormone and follicle stimulating hormone levels relative to the control group. (Bowen, Isley, & Atkinson, 2000).
In another study, 585 normal and healthy men between the
ages of 70 and 87 years were tested for luteinizing levels to try
WRÀQGDUHODWLRQVKLSEHWZHHQOXWHLQL]LQJKRUPRQHOHYHOVDQGLVVXHVZLWKPHPRU\UHFDOO0HQZHUHFKRVHQVSHFLÀFDOO\EHFDXVH
in previous studies, this correlation had not been demonstrated
for men as strongly as in women. The study found that higher
levels of luteinizing hormone were related to worse performance on CVLT-II which is a test for immediate recall (Hyde,
et al., 2010).
In an even larger study that evaluated the effects of elevated levels of gonadotropins on cognition in elderly women, 649
women without dementia were given cognitive testing and
blood samples were taken. Plasma levels of luteinizing hormone,
estradiol, follicle stimulating hormone, and beta amyloid were
recorded.The study found that elevated levels of luteinizing hormone were associated with worse cognitive performance and
depression (Rodrigues, et al., 2008).
In the Australian Imaging Biomarkers and Lifestyle study of
aging, more than 1000 people were assembled to conduct a longitudinal study to aid understanding Alzheimer’s beginnings and
progression. The subjects were given full cognitive evaluation,
their blood was analyzed and many of them had their brains
imaged by MRI machines and various brain imaging technology.
The participants were grouped by cognitive issues.The categories
were healthy, subjective memory impairment, mildly impaired, and
Alzheimer’s patients. It was not the primary focus of the study to

In studying disease pathology, and possible treatment options, it
is not always possible to use humans as some potential treatments may have negative side effects, it is therefore better to
ÀUVWWHVWWKHLUSRWHQWLDOZLWKDQLPDOV0LFHDUHRIWHQXVHGEHcause of their biological similarities to humans. Some researchers have studied ties between luteinizing hormone, beta amyloid
plaque, and cognition in transgenic mice that have genes that
lead to Alzheimer’s disease development.To test for cognition in
mice, researchers use a test known as ‘spontaneous alternation’.
It is a behavioral test which tests spatial learning and memory. In
this test, the animal is put in the center of a maze and can move
freely. Spatial memory is tested by observing whether the mouse
remembers which arms of the maze it has already explored. It
VKRXOGEHQRWHGWKDWWKHWHVWUHVXOWVFDQDOVREHLQÁXHQFHGE\
factors such as attention or sensory stimuli (Hughes, 2004).
In a study of 21, one month old transgenic Tg2576 mice, the
effects of high luteinizing hormone levels in the mice on amyloid
beta plaque deposition were tested. The animals were bred to
over-express human APP to ensure that there would be beta amyloid plaque buildup. In this breed in general, beta amyloid plaque
JURZVWKURXJKRXWWKHÀUVWPRQWKVRIDJHDQGE\WKHWLPHWKH\
are 10 months old, the level of beta amyloid plaque is enough to
form an accumulation. The mice were randomly split into two
groups. One was a control group that received saline solution
and the second group received leuprolide. The mice were tested
with mazes to examine spontaneous alternation and their blood
levels of luteinizing hormone were assayed to evaluate the effects
of leuprolide.The brains were sliced on the sagittal plane and preVHUYHGWRÀQGWKHDPRXQWRIEHWDDP\ORLGGHSRVLWLRQ7KHPLFH
WKDWZHUHWUHDWHGZLWKOHXSUROLGHZHUHIRXQGWRKDYHVLJQLÀFDQWO\
lower levels of luteinizing hormone compared to the saline group
especially 3 months after the treatment. The leuprolide-treated
mice performed better on the maze task than the control group.
Additionally, the leuprolide-treated mice had lower levels of beta
amyloid plaque and this correlated with the improved cognition
(Casadesus, et al., 2006).
Mice which were bred to have an elevated level of amyloid
beta precursor proteins had higher levels of luteinizing hormone and faster cognitive decline. The group that was treated
with leuprolide, to help lower luteinizing hormone levels, had
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less beta amyloid plaque deposition and better cognitive performance than the controls.
In another study done with mice,Tg2576 mice that were bred
to express the human amyloid precursor gene were crossed
with mice that had the genes for luteinizing hormone receptors
removed, so that they couldn’t use luteinizing hormone. There
were two control groups. One of the control groups were APP
expressing mice that were not crossbred. A second control
group was mice that had luteinizing hormone receptors and did
not express the human APP gene. Finally, a group of normal mice
was a third control. The animals were raised for 16 months,
VDFULÀFHG DQG WKHQ WKHLU EUDLQV ZHUH VHFWLRQHG $Q LPDJLQJ
software was used to compare the beta amyloid concentrations
LQWKHEUDLQVRIHDFKJURXS7KHPRVWLPSRUWDQWÀQGLQJLQWKLV
VWXG\ZDVWKDWWKHUHZDVVLJQLÀFDQWO\OHVVEHWDDP\ORLGSODTXH
in the mice which had luteinizing hormone receptor knockout
compared to the mice with APP that did have luteinizing hormone receptors. (Lukacs, Hiatt, Lei, & Rao, 1995)
7KHVWXGLHVPHQWLRQHGDERYHDOOÀQGDFRUUHODWLRQEHWZHHQ
elevated luteinizing hormone levels and Alzheimer’s disease or
beta amyloid plaque deposition. If luteinizing hormone is a part
of the cause of Alzheimer’s, it presents exciting treatment possibilities through the lowering of luteinizing hormone levels especially to prevent deterioration in those at risk for Alzheimer’s. A
promising candidate for a medication that can accomplish this
safely is leuprolide.

The results were that Leuprolide can aid in slower regression and improved cognition in Alzheimer’s patients. Voyager
Pharmaceuticals is not currently pursuing further research into
Lupron and most likely will not do so in the future as it declared
bankruptcy in 2012. In an interview for medicalresearch.com,
Richard Bowen cited lack of marketability to account for the
dearth in leuprolide research. “Unfortunately, there is no intellectual property protection for this treatment making it unlikely
that a pharmaceutical company will take the lead.” (R. Bowen).
,WLVYLWDOO\LPSRUWDQWWRÀQGDFXUHIRU$O]KHLPHU·VDQGSHUKDSV
the funding will come from a government the government or
foundation, and leuprolide research will be continued.

Conclusion
Alzheimer’s disease is a common debilitating disease that is
one of the main leading causes of death in the United States.
One of the main changes detected in the brain of a patient
with Alzheimer’s disease is beta amyloid plaque. These plaques
can only be detected after death, upon autopsy. Studies have
shown that a rise in luteinizing hormone is linked to increased
beta amyloid plaque and Alzheimer’s. Studies have been done
to lower Gonadotropin-releasing hormone levels through the
treatment of Leuprolide acetate, a Gonadotropin-releasing horPRQHDJRQLVW7KLVWUHDWPHQWLVQRWEHLQJÀQDQFLDOO\EDFNHGDQG
is therefore on hold for the time being; however, the possibility
of this treatment for Alzheimer’s disease is somewhat promising
and deserving of more research.

Leuprolide as a Treatment for Alzheimer’s Disease
Leuprolide interferes with GnRH in humans and therefore
brings about lower levels of luteinizing hormone. It is not an
approved treatment for Alzheimer’s disease as of now. However,
since leuprolide is an approved treatment for prostate cancer,
some studies have observed the effect that leuprolide has had
on Alzheimer’s disease in the patients using it for other reasons. Clinical trials are currently underway to test this possibility under the code ALADDIN which is an abbreviation for
Antigonadotropin-Leuprolide in Alzheimer’s Disease Drug
Investigation
One study of the impact of leuprolide on Alzheimer’s disease
in patients with prostate cancer was done in 2010. The study
looked at the risk of death by Alzheimer’s disease in 6,647 men
who were treated for prostate cancer. In the study, 1700 men
who were treated with leuprolide were compared to 4,947
controls who were treated using other drugs that do not limit
luteinizing hormone production. After 4 years of follow up, 81
of the group in the study had died from Alzheimer’s disease.
Those who died of Alzheimer’s were found to be from the control group rather than from the group of patients who took
leuprolide for at least 4 months (D’Amico, Braccioforte, Moran,
& Chen, 2010).
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